<DOC>
	<DOCNO>NCT00690677</DOCNO>
	<brief_summary>The purpose study determine effect study drug , LBH589 , patient metastatic colorectal cancer continue grow despite previous treatment .</brief_summary>
	<brief_title>Phase II Trial LBH589 Refractory Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Male female patient age ≥ 18 year old Patients measurable metastatic colorectal cancer Refractory least 2 standard chemotherapy/biologic regimen include 5FU , oxaliplatin , irinotecan , bevacizumab , cetuximab combination thereof ECOG Performance Status ≤ 2 Ability provide write informed consent obtain prior participation study relate procedure perform Laboratory value follow : Neutrophil count &gt; 1500/mm3 Platelet count &gt; 100,000/mm3L Hemoglobin ≥ 9 g/dL AST/SGOT ALT/SGPT ≤ 2.5 x upper limit normal ( ULN ) ≤ 5.0 x ULN transaminase elevation due disease involvement Serum bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 ml/min Total serum calcium ( correct serum albumin ) ionize calcium ≥ LLN Serum potassium ≥ LLN Serum sodium ≥ LLN Serum albumin ≥ LLN 3g/dl Patients elevated Alkaline Phosphatase due bone metastasis enrol Baseline MUGA ECHO must demonstrate LVEF ≥ low limit institutional normal TSH free T4 within normal limit ( patient may thyroid hormone replacement ) Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first administration study treatment . must willing use two method contraception one barrier method study 3 month last study drug administration Radiographically bidimensionally measurable disease previously irradiate . If patient previous radiation marker lesion ( ) , must evidence progression since radiation Life expectancy must great 12 week Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first LBH589 treatment Impaired cardiac function include one following : Screening ECG QTc &gt; 450 msec confirm central laboratory prior enrollment study Patients congenital long QT syndrome History sustain ventricular tachycardia Any history ventricular fibrillation torsades de pointes Bradycardia define heart rate &lt; 50 beat per minute . Patients pacemaker heart rate ≥ 50 beat per minute eligible . Patients myocardial infarction unstable angina within 6 month study entry Congestive heart failure ( NY Heart Association class III IV ) Right bundle branch block leave anterior hemiblock ( bifasicular block ) Uncontrolled hypertension Concomitant use drug risk cause torsades de pointes Concomitant use CYP3A4 inhibitor Patients unresolved diarrhea &gt; CTCAE grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 Other concurrent severe and/or uncontrolled medical condition Patients receive chemotherapy , investigational drug undergone major surgery &lt; 4 week prior start study drug recover side effect therapy . Concomitant use anticancer therapy radiation therapy Women pregnant breast feed woman childbearing potential ( WOCBP ) willing use double barrier method contraception study 3 month end treatment . One method contraception must barrier method . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day first administration oral LBH589 Male patient whose sexual partner WOCBP use double method contraception study 3 month end treatment . One method must condom Patients history another primary malignancy within 5 year curatively treat CIS cervix , basal squamous cell carcinoma skin Patients know positivity human immunodeficiency virus ( HIV ) ) hepatitis C ; baseline test HIV hepatitis C require Patients significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>LBH589</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Refractory Colorectal Cancer</keyword>
</DOC>